ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 1589 • ACR Convergence 2025

    Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation

    Punchalee Kaenmuang1, Nina Goldman2, Arthihai Srirangan1, Fiammetta Danzo1, Wing-Ho Yip1, Ali Taki3, Shereen Boreland1, Benedetta Vitri1, Carmel JW. Stock1, Christopher Denton4, Athol U. Wells1, Voon H. Ong5, Piersante Sestini6 and Elisabetta A. Renzoni1, 1Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy’s and St Thomas’ National Health Service Foundation Trust, London, England, United Kingdom, 2Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, 3Royal Free Hospital, London, England, United Kingdom, 4University College London, UK, London, United Kingdom, 5Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 6Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Toscana, Italy

    Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…
  • Abstract Number: 1030 • ACR Convergence 2025

    Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study

    Sarah Pimple1, Alanna Chamberlain1, Sara Achenbach2, Cynthia Crowson3 and Elena myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Stewartvillle, MN

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of developing atrial fibrillation (AF). However, recent data on trends in incidence of AF…
  • Abstract Number: 0459 • ACR Convergence 2025

    Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

    Rinko Katsuda1, Akiko Kitagawa1, Masayuki Azukizawa2, Musuzu Fujimori1 and Tetsuji Kawamura3, 1Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, 2Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, 3Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
  • Abstract Number: 2087 • ACR Convergence 2025

    Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis

    Erfan Afshar1 and Andrew Long2, 1VCUSOM, Richmond, VA, 2Virginia Commonwealth University Health System, Midlothian, VA

    Background/Purpose: Carbamazepine has shown chondroprotective effects in OA animal models by modulating Nav1.7 channels. This study aimed to examine the association between Carbamazepine use and…
  • Abstract Number: 1579 • ACR Convergence 2025

    Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease

    Maria Iacovantuono1, Nicholas landini2, lisa Jungblut3, Florian Käs4, Rucsandra Dobrota5, Sinziana Muraru6, Carina Mihai7, Muriel Elhai8, Mike Becker9, Maria Sole Chimenti10, Thomas Frauenfelder3, Anna-Maria Hoffmann-Vold11, Oliver Distler12 and Cosimo Bruni13, 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, 2Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, 3Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 6University of Zurich, University Hospital Zurich, Zürich, Switzerland, 7University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, 9Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 10Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, 11Oslo University Hospital, Oslo, Norway, 12Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 13Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
  • Abstract Number: 0714 • ACR Convergence 2025

    Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort

    Alvaro Oyarce-Calderón1, Allison Figueroa-Sánchez2, Leonor León-Yaurimucha2, Rocío Gamboa-Cárdenas3, Zoila Rodríguez-Bellido4, Risto Perich-Campos5, Graciela Alarcón6, Manuel Ugarte-Gil7 and Victor Pimentel-Quiroz8, 1Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, 2Universidad Científica del Sur, Lima, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 6The University of Alabama at Birmingham, Oakland, CA, 7Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 8Universidad Científica del Sur, San Isidro, Peru

    Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
  • Abstract Number: 0454 • ACR Convergence 2025

    Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights

    Laura Galindo Domínguez1, Belen Acasuso1, Vanesa Balboa2, Juan Cañete3, Benjamin Fernández-Gutiérrez4, Isidoro Gonzalez-Alvaro5, jose Luis Pablos6, Carmen Bejerano-Herreria7, Maite silva8, Ignacio rego Pérez9, Cristina Ruiz-Romero10, Francisco J De-Toro-Santos11, Natividad Oreiro12 and francisco J Blanco13, 1Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Galicia, Spain, 2Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, 3Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 4Department of Rheumatology and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain., Madrid, Madrid, Spain, 5Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, 6Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre, Complutense University of Madrid, Madrid, Madrid, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 8Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, 9Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, 10Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, 11Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, 12CHUAC, La Coruna, Spain, 13INIBIC-University of A Coruña, A Coruña, Galicia, Spain

    Background/Purpose: Optimization of biologic DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six…
  • Abstract Number: 2667 • ACR Convergence 2025

    Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models

    Berkay Aktas1, Enes Azman1, Yusuf Ecren Oner2, kadir Kaya2, husnu Mert Yuksel3, Ali Hosgel2, Dilan Karahan2, Zehra Beyza Coban2, Kerem parlar4, Ozgur Can Kilinc1, Beste Acar1 and serdal Ugurlu5, 1Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 4Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, 5Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by MEFV mutations. Amyloidosis remains its most serious complication, with several risk factors reported…
  • Abstract Number: 1885 • ACR Convergence 2025

    Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study

    Carl Turesson1, Linnea arvidsson2, Emil Rydell1 and Ulf Bergström3, 1Lund University, Malmö, Sweden, 2Lund University, Malmö, 3Lund University, Malmö, Sweden

    Background/Purpose: Smoking is an established risk factor for rheumatoid arthritis (RA), and there is also evidence for an association with socioeconomic factors. As RA is…
  • Abstract Number: 1561 • ACR Convergence 2025

    Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion

    Carlos de la Puente-Bujidos1, Antia Garcia Fernandez2, Verónica García García1, Jesús Loarce3 and Sandra Garrote-Corral1, 1Ramón y Cajal University Hospital, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Ramón y Cajal University Hospital, Madrid, Spain

    Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
  • Abstract Number: 0682 • ACR Convergence 2025

    Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

    Alex Luta1, Saloni Mitchell2 and Virginia Steen3, 1Hospital for Special Surgery, New York, NY, 2Mount Sinai West and Morningside, New York, NY, 3Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
  • Abstract Number: 0437 • ACR Convergence 2025

    Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention

    Anokhi Saklecha1, Amelia Khoo2, Sierra Mendelsohn2, Abhijeet Danve3, Mei Xue Dong4 and Lisa Suter2, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, 4Yale-New Haven Medical Center, new haven, CT

    Background/Purpose: Rheumatoid arthritis (RA) is associated with a 1.5 to 2 fold increased risk of cardiovascular disease (CVD) due to systemic inflammation and endothelial dysfunction.…
  • Abstract Number: 2658 • ACR Convergence 2025

    Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network

    Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
  • Abstract Number: 1884 • ACR Convergence 2025

    The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study

    Rebecka Bäcklund1, Ulf Bergström1, Michele Compagno1, Linnea arvidsson2, Emil Rydell3, Emily Sonestedt1 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Lund University, Malmö, 3Lund University, Malmö, Sweden

    Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). The impact of such lifestyle factors on the risk of RA may differ…
  • Abstract Number: 1478 • ACR Convergence 2025

    Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus

    Bin Zhou1, QIn Huang2, Pan Wang3 and Qiguo Cui4, 1Nanfang Hospital, Guangzhou, Guangdong, China (People's Republic), 2Nanfang Hospital, Guangzhou, China (People's Republic), 3southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), 4Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology